Bathi operasional sadurunge amortisasi: Ocugen Inc (OCGN)

Ocugen, Inc. (OCGN) is developing gene therapy while awaiting FDA approval and the transition of its OCU400 drug into the final stage of trials. EBITDA cash flow confirms this potential, with the 0.00 level serving as a critical benchmark. However, manufacturing outsourcing creates a dependency on contractors, and the speculative nature of Phase 1/2 data expectations, coupled with current expenditures, increases investment risks.

This metric reflects the net cash flow from core operations before depreciation and interest, allowing for an assessment of the business's internal efficiency without the influence of debt policy. By analyzing EBITDA volatility, an investor can see the real ability of Ocugen, Inc. (OCGN) to generate cash, which is currently limited due to geopolitical barriers and sanctions hindering international clinical trials of gene therapies.